PCM
RARE icon

Penserra Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Penserra Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-518
Closed -$42K – 1117
2020
Q3 		$42K Buy
+518
New +$42.9K ﹤0.01% 649

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Penserra Capital Management's RARE Position: Q4 2020 in Review

Penserra Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2020, closing a stake of 518 shares — an estimated $42K sold.

Penserra Capital Management first reported a position in RARE in Q3 2020 and held it in 1 quarter. The position peaked at $42K in Q3 2020. 252 funds tracked by Wall St. Rank hold RARE as of Q4 2020.

  • Penserra Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2020 after selling out during the quarter.
  • Penserra Capital Management sold 518 Ultragenyx Pharmaceutical shares in Q4 2020, an estimated $42K.
  • Penserra Capital Management first reported a position in Ultragenyx Pharmaceutical in Q3 2020 and held it in 1 quarter.
  • Penserra Capital Management's Ultragenyx Pharmaceutical position peaked at $42K in Q3 2020.
  • 252 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2020.

Based on Penserra Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.